APOA5 and hypertriglyceridemia: Therefore, our findings indicated that olanzapine-induced reduction of plasma apoA5 levels could result from the retardation of hepatic apoA5 secretion (rather than hepatic apoA5 production/synthesis), which consequently led to hypertriglyceridemia.